FrancophonIA/ELRC3.0 huggingface dataset:
English: EU/1/06/372/017 7 film-coated tablets EU/1/06/372/018 14 film-coated tablets EU/1/06/372/019 28 film-coated tablets EU/1/06/372/020 30 film-coated tablets EU/1/06/372/021 56 film-coated tablets EU/1/06/372/022 90 film-coated tablets EU/1/06/372/023 98 film-coated tablets EU/1/06/372/024 280 film-coated tablets EU/1/06/372/031 56x1 film-coated tablet (unit dose) EU/1/06/372/032 98x1 film-coated tablet (unit dose) EU/1/06/372/033 280x1 film-coated tablet (unit dose)
Croatian: EU/1/06/372/017 7 filmom obloženih tableta EU/1/06/372/018 14 filmom obloženih tableta EU/1/06/372/019 28 filmom obloženih tableta EU/1/06/372/020 30 filmom obloženih tableta EU/1/06/372/021 56 filmom obloženih tableta EU/1/06/372/022 90 filmom obloženih tableta EU/1/06/372/023 98 filmom obloženih tableta EU/1/06/372/024 280 filmom obloženih tableta EU/1/06/372/031 56x1 filmom obloženih tableta (jedinična doza) EU/1/06/372/032 98x1 filmom obloženih tableta (jedinična doza) EU/1/06/372/033 280x1 filmom obloženih tableta (jedinična doza)
English: EU/1/06/372/001 7 film-coated tablets EU/1/06/372/002 14 film-coated tablets EU/1/06/372/003 28 film-coated tablets EU/1/06/372/004 30 film-coated tablets EU/1/06/372/005 56 film-coated tablets EU/1/06/372/006 90 film-coated tablets EU/1/06/372/007 98 film-coated tablets EU/1/06/372/008 280 film-coated tablets EU/1/06/372/025 56x1 film-coated tablet (unit dose) EU/1/06/372/026 98x1 film-coated tablet (unit dose) EU/1/06/372/027 280x1 film-coated tablet (unit dose)
Croatian: EU/1/06/372/001 7 filmom obloženih tableta EU/1/06/372/002 14 filmom obloženih tableta EU/1/06/372/003 28 filmom obloženih tableta EU/1/06/372/004 30 filmom obloženih tableta EU/1/06/372/005 56 filmom obloženih tableta EU/1/06/372/006 90 filmom obloženih tableta EU/1/06/372/007 98 filmom obloženih tableta EU/1/06/372/008 280 filmom obloženih tableta EU/1/06/372/025 56x1 filmom obloženih tableta (jedinična doza) EU/1/06/372/026 98x1 filmom obloženih tableta (jedinična doza) EU/1/06/372/027 280x1 filmom obloženih tableta (jedinična doza)
English: What Copalia looks like and contents of the pack Copalia 5 mg/80 mg tablets are round and dark yellow with “NVR” on one side and “NV” on the other side.
Croatian: Copalia 5 mg/80 mg tablete su okrugle, tamnožute tablete, s oznakom „NVR“ na jednoj strani i „NV“ na drugoj strani.
English: EU/1/06/372/009 7 film-coated tablets EU/1/06/372/010 14 film-coated tablets EU/1/06/372/011 28 film-coated tablets EU/1/06/372/012 30 film-coated tablets EU/1/06/372/013 56 film-coated tablets EU/1/06/372/014 90 film-coated tablets EU/1/06/372/015 98 film-coated tablets EU/1/06/372/016 280 film-coated tablets EU/1/06/372/028 56x1 film-coated tablet (unit dose) EU/1/06/372/029 98x1 film-coated tablet (unit dose) EU/1/06/372/030 280x1 film-coated tablet (unit dose)
Croatian: EU/1/06/372/009 7 filmom obloženih tableta EU/1/06/372/010 14 filmom obloženih tableta EU/1/06/372/011 28 filmom obloženih tableta EU/1/06/372/012 30 filmom obloženih tableta EU/1/06/372/013 56 filmom obloženih tableta EU/1/06/372/014 90 filmom obloženih tableta EU/1/06/372/015 98 filmom obloženih tableta EU/1/06/372/016 280 filmom obloženih tableta EU/1/06/372/028 56x1 filmom obloženih tableta (jedinična doza) EU/1/06/372/029 98x1 filmom obloženih tableta (jedinična doza) EU/1/06/372/030 280x1 filmom obloženih tableta (jedinična doza)
English: if you have narrowing of the aortic valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body).
Croatian: (Također je bolje izbjegavati Copaliu u ranoj trudnoći, vidjeti dio Trudnoća). ako imate jako nizak krvni tlak (hipotenzija). ako imate suženje aortnog zaliska (stenoza aorte) ili kardiogeni šok (stanje u kojem Vaše srce ne može opskrbiti tijelo dovoljnom količinom krvi). ako patite od zatajivanja srca nakon srčanog udara.
English: Magyarország Novartis Hungária Kft. Tel.: +36 1 457 65 00
Croatian: Slovenská republika Novartis Slovakia r.o. Tel: +421 2 5542 5439
English: The active substances of Copalia are amlodipine (as amlodipine besylate) and valsartan.
Croatian: Djelatne tvari u Copalii su amlodipin (u obliku amlodipinbesilata) i valsartan.
English: Novartis Pharma B.V. Tel: +31 26 37 82 111
Croatian: Vifor Pharma España, S.L. Tel: +34 902 12 11 11
English: The full EPAR for Lifmior can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Lifmior nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: In adults, the usual recommended dose is 25 mg twice a week or 50 mg once a week.
Croatian: Uobičajena preporučena doza za odrasle jest 25 mg dvaput tjedno ili 50 mg jednom tjedno.
English: Lifmior is identical to Enbrel, which has been authorised in the EU since 3 February 2000.
Croatian: Lifmior je jednak lijeku Enbrel, koji je odobren u EU-u 3. veljače 2000. godine.
English: This is a summary of the European public assessment report (EPAR) for Lifmior.
Croatian: Ovo je sažetak Europskog javnog izvješća o procjeni (EPAR) lijeka Lifmior.
English: In rheumatoid arthritis, five studies have been carried out involving around 2,200 patients.
Croatian: U vezi s reumatoidnim artritisom provedeno je 5 ispitivanja u kojima je sudjelovalo približno 2 200 bolesnika.
English: This compared with around a quarter of the patients receiving placebo.
Croatian: To je bio slučaj u usporedbi s četvrtinom bolesnika koji su primili placebo.
English: The patient or carer can give the injection if they have been trained appropriately.
Croatian: Bolesnik ili njegovatelj mogu dati injekciju ako su odgovarajuće osposobljeni.
English: What measures are being taken to ensure the safe and effective use of Lifmior?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Lifmior?
English: By blocking TNF, etanercept reduces the inflammation and other symptoms of the diseases.
Croatian: Blokiranjem TNF-a etanercept ublažuje upalu i druge simptome bolesti.
English: Lifmior is an anti-inflammatory medicine for treating the following diseases:
Croatian: Lifmior je protuupalni lijek za liječenje sljedećih bolesti:
English: In children, the dose will depend on body weight.
Croatian: Doza za djecu utvrdit će se u skladu s tjelesnom masom.
English: Lifmior must not be used in patients who have or are at risk of sepsis (when bacteria and toxins circulate in the blood and start to damage the organs), or in patients with infections.
Croatian: Lifmior se ne smije primjenjivati u bolesnika koji imaju sepsu ili u kojih postoji rizik od sepse (kada bakterije i toksini cirkuliraju krvotokom i počnu oštećivati organe) ili u bolesnika s infekcijama.
English: Other information about Lifmior
Croatian: Ostale informacije o lijeku Lifmior
English: Why is Lifmior approved?
Croatian: Zašto je Lifmior odobren?
English: Lifmior is mostly used when these conditions are severe or moderately severe, or when other treatments have not worked well enough.
Croatian: Lifmior se uglavnom primjenjuje kada su navedene bolesti teške ili umjereno teške ili kada liječenje nije bilo dovoljno uspješno.
English: Further studies have been carried out in over 2,300 patients with other inflammatory diseases (juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and axial spondyloarthritis).
Croatian: Provedena su daljnja ispitivanja na više od 2 300 bolesnika oboljelih od drugih upalnih bolesti (juvenilnog idiopatskog artritisa, psorijatičnog artritisa, ankilozantnog spondilitisa, plak psorijaze i aksijalnog spondiloartritisa).
English: In a fourth study of rheumatoid arthritis patients who had not taken methotrexate before, those receiving 25 mg Lifmior twice a week had less joint damage than those taking methotrexate alone after 12 and 24 months.
Croatian: U četvrtom ispitivanju na bolesnicima oboljelima od reumatoidnog artritisa koji prethodno nisu uzimali metotreksat, bolesnici koji su dvaput tjedno primali 25 mg lijeka Lifmior imali su manja oštećenja zglobova u bolesnika koji su uzimali samo metotreksat nakon 12 i 24 mjeseca.
English: The CHMP therefore concluded that Lifmior's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) stoga je zaključio da koristi od lijeka Lifmior nadmašuju rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
English: What is Lifmior and what is it used for?
Croatian: Što je Lifmior i za što se uzima?
English: It is not intended to provide practical advice on how to use Lifmior.
Croatian: Svrha sažetka nije pružiti praktične savjete o primjeni lijeka Lifmior.
English: The most common side effects with Lifmior (seen in more than 1 patient in 10) are injection site reactions (including bleeding, bruising, redness, itching, pain and swelling) and infections (including colds, and lung, bladder and skin infections).
Croatian: Najčešće su nuspojave lijeka Lifmior (uočene u više od 1 na 10 osoba) reakcije na mjestu ubrizgavanja injekcije (uključujući krvarenje, nastanak modrica, crvenilo, svrbež, bol i oticanje) i infekcije (uključujući prehladu te infekcije pluća, mjehura i kože).
English: The company that markets Lifmior will provide educational material for doctors expected to prescribe the product to teach patients how to use the pre-filled pen correctly and a special alert card for patients so they can recognise serious side effects and know when to seek urgent attention from their doctor.
Croatian: Tvrtka koja stavlja lijek Lifmior u promet dostavit će obrazovne materijale liječnicima koji će propisati navedeni proizvod kako bi mogli podučiti bolesnike kako ispravno upotrebljavati napunjenu brizgalicu te posebnu karticu s upozorenjima za bolesnike kako bi mogli prepoznati teške nuspojave i znati kada zatražiti hitnu liječničku pomoć.
English: What is the risk associated with Lifmior?
Croatian: Koji su rizici povezani s lijekom Lifmior?
English: Three of these studies in patients who had taken arthritis medicines in the past showed about two-thirds of the patients who received Lifmior had a reduction in symptoms of 20% or more after three months based on a standard rating score (ACR 20).
Croatian: Tri navedena ispitivanja na bolesnicima koji su u prošlosti uzimali lijekove protiv artritisa pokazala su, u dvije trećine bolesnika koji su primili Lifmior, smanjenje simptoma za 20 % ili više nakon tri mjeseca na temelju standardne skale rezultata (ACR 20).
English: It contains the active substance etanercept.
Croatian: Sadrži djelatnu tvar etanercept.
English: Patients developing a serious infection should stop Lifmior treatment.
Croatian: Bolesnici u kojih je došlo do teških infekcija trebaju prestati uzimati lijek Lifmior.
English: Lifmior is given as an injection under the skin.
Croatian: Lifmior se daje kao potkožna injekcija.
English: Several studies have shown that Lifmior is more effective at reducing symptoms of inflammatory conditions than placebo (a dummy treatment) or a comparator medicine.
Croatian: Nekoliko ispitivanja pokazalo je da je lijek Lifmior djelotvorniji u smanjenju simptoma upalnih bolesti od placeba (prividnog liječenja) ili usporednog lijeka.
English: These studies also showed that Lifmior produced a greater improvement in symptoms than placebo after three to four months using various standard rating scores such as ACR, ASAS and PASI.
Croatian: Ta su ispitivanja također pokazala da je lijek Lifmior doprinio znatnom smanjenju simptoma u odnosu na placebo nakon tri do četiri mjeseca na temelju različitih standardnih skala rezultata kao što su ACR, ASAS i PASI.
English: Treatment is started and supervised by specialised doctors with experience in diagnosing and treating the diseases Lifmior is used for.
Croatian: Liječenje započinju i nadgledaju liječnici specijalisti s iskustvom u dijagnosticiranju i liječenju bolesti za koje se lijek Lifmior primjenjuje.
English: Lifmior is effective at reducing symptoms in several inflammatory conditions and its side effects are considered manageable.
Croatian: Lifmior je učinkovit u smanjenju simptoma nekoliko upalnih bolesti i njegove je nuspojave moguće kontrolirati.
English: The active substance in Lifmior, etanercept, is a protein that has been designed to block the activity of a substance called tumour necrosis factor (TNF).
Croatian: Etanercept, djelatna tvar u lijeku Lifmior, je protein namijenjen blokiranju djelovanja tvari naziva faktor tumorske nekroze (TNF).
English: A fifth study showed that Lifmior on its own or in combination with methotrexate was more effective than methotrexate alone.
Croatian: Peto ispitivanje pokazalo je da je uzimanje lijeka Lifmior kao monoterapija ili u kombinaciji s metotreksatom djelotvornije od uzimanja metotreksata kao monoterapije.
English: • certain forms of juvenile idiopathic arthritis (inflammation of joints in children and adolescents)
Croatian: • određenih oblika juvenilnog idiopatskog artritisa (upale zglobova u djece i adolescenata)
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lifmior have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Lifmior nalaze se također u sažetku opisa svojstava lijeka i uputi o lijeku.
English: What benefits of Lifmior have been shown in studies?
Croatian: Koje su koristi lijeka Lifmior dokazane u ispitivanjima?
English: How is Lifmior used?
Croatian: Kako se Lifmior koristi?
English: This substance is involved in causing inflammation and is found at high levels in patients with the diseases that Lifmior is used to treat.
Croatian: Ta tvar sudjeluje u uzrokovanju upale te se u visokim razinama nalazi u bolesnika oboljelih od bolesti za čije se liječenje primjenjuje Lifmior.
English: For more information about treatment with Lifmior, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Lifmior pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: For detailed information on the use of Lifmior in all conditions, see the summary of product characteristics (also part of the EPAR).
Croatian: Detaljne informacije o primjeni Lifmiora za sve bolesti potražite u sažetku opisa svojstva proizvoda (također dio EPAR-a).
English: • axial spondyloarthritis (a chronic inflammatory disease of the spine) in adults when there are no abnormalities seen on x-ray.
Croatian: • aksijalnog spondiloartritisa (kronične upalne bolesti kralježnice) u odraslih kada abnormalnosti nisu vidljive na rendgenskoj snimci.
English: For practical information about using Lifmior, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Lifmior bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
English: How does Lifmior work?
Croatian: Kako Lifmior djeluje?
English: • plaque psoriasis (a disease causing red, scaly patches on the skin) in adults and children
Croatian: • plak psorijaze (bolesti koja na koži uzrokuje crvenkasta žarišta koja se ljušte) u djece i odraslih
English: • ankylosing spondylitis (a disease causing inflammation of the joints of the spine) in adults
Croatian: • ankilozantnog spondilitisa (bolesti koja uzrokuje upalu zglobova kralježnice) u odraslih
English: • rheumatoid arthritis (a disease causing inflammation of the joints) alone or with methotrexate in adults
Croatian: • reumatoidnog artritisa (bolesti koja uzrokuje upalu zglobova) kao monoterapija ili u kombinaciji s metotreksatom u odraslih
English: • psoriatic arthritis (psoriasis with inflammation of the joints) in adults
Croatian: • psorijatičnog artritisa (psorijaze s upalom zglobova) u odraslih
English: For the full list of all side effects reported with Lifmior, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Lifmior potražite u uputi o lijeku.
English: Kivexa is taken as one tablet once a day.
Croatian: Kivexa se uzima kao jedna tableta jednom na dan.
English: It should only be given to patients who weigh at least 25 kg.
Croatian: Smije se primjenjivati samo u bolesnika s težinom od najmanje 25 kg.
English: The full EPAR for Kivexa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Kivexa nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: In the first study, 66% (253 out of 384) of the patients taking abacavir once a day had viral loads below 50 copies/ml after 48 weeks of treatment, compared with 68% (261 out of 386) of the patients taking it twice a day.
Croatian: U prvom ispitivanju 66 % (253 od 384) bolesnika koji su uzimali abakavir jednom na dan imalo je virusno opterećenje od 50 kopija/ml nakon 48 tjedana liječenja, u usporedbi sa 68 % (261 od 386) bolesnika koji su uzimali lijek dvaput na dan.
English: Other information about Kivexa
Croatian: Ostale informacije o lijeku Kivexa
English: Both active substances have been available in the European Union (EU) since the late 1990s: abacavir has been authorised as Ziagen since 1999, and lamivudine has been authorised as Epivir since 1996.
Croatian: Obje djelatne tvari dostupne su u Europskoj uniji (EU) od kasnih 1990.-tih: abakavir je odobren pod nazivom Ziagen od 1999., a lamivudin je odobren pod nazivom Epivir od 1996.
English: Kivexa has been studied in three main studies involving a total of 1,230 patients.
Croatian: Lijek Kivexa ispitivan je u tri glavna ispitivanja kojima je bilo obuhvaćeno ukupno 1.230 bolesnika.
English: The main measure of effectiveness was the change in the level of HIV in the blood (viral load) after 24 or 48 weeks of treatment.
Croatian: Glavno mjerilo djelotvornosti bila je promjena u razini HIV-a u krvi (virusno opterećenje) nakon 24 ili 48 tjedana liječenja.
English: Kivexa does not cure HIV infection or AIDS, but can delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Croatian: Kivexa ne liječi zarazu HIV-om ili AIDS, no može odgoditi oštećenje imunosnog sustava i razvoj infekcija te bolesti povezanih s AIDS-om.
English: Hypersensitivity reactions occur in patients taking Kivexa, usually within the first six weeks of treatment, and can be life-threatening.
Croatian: Reakcije preosjetljivosti pojavljuju se u bolesnika koji uzimaju lijek Kivexa obično u roku od prvih šest tjedana liječenja i mogu biti opasne po život.
English: What measures are being taken to ensure the safe and effective use of Kivexa?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Kivexa?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Kivexa on 17 December 2004.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Kivexa na snazi u Europskoj uniji od 17. prosinca 2004.
English: Both doses of abacavir, taken in combination with lamivudine and other antiviral medicines, were equally effective in reducing viral loads.
Croatian: Obje doze abakavira, uzete u kombinaciji s lamivudinom i drugim protuvirusnim lijekovima, bile su podjednako djelotvorne u smanjivanju virusnog opterećenja.
English: Before starting treatment with abacavir, all patients should have a test to find out if they have a gene called ‘HLA-B (type 5701)'.
Croatian: Prije početka terapije lijekom abakavir svi se bolesnici trebaju testirati kako bi se utvrdilo imaju li gen „HLA-B (tip 5701)”.
English: Kivexa is a medicine that contains two active substances, abacavir (600 mg) and lamivudine (300 mg).
Croatian: Kivexa je lijek koji sadrži dvije djelatne tvari: abakavir (600 mg) i lamivudin (300 mg).
English: For more information and the full list of restrictions, see the package leaflet.
Croatian: Više informacija i potpuni popis ograničenja potražite u uputi o lijeku.
English: Treatment with Kivexa should be stopped promptly if the patient has a hypersensitivity reaction.
Croatian: Liječenje lijekom Kivexa treba odmah prekinuti ako bolesnik ima reakciju preosjetljivosti.
English: Therefore, the studies compared abacavir taken at a dose of 600 mg once a day and at a dose of 300 mg twice a day, in combination with lamivudine and one or two other antiviral medicines.
Croatian: Stoga je ispitivanjima uspoređen abakavir u dozi od 600 mg jednom na dan i u dozi od 300 mg dvaput na dan, u kombinaciji s lamivudinom i jednim ili dvama drugim protuvirusnim lijekovima.
English: This document is a summary of the European public assessment report (EPAR) for Kivexa.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Kivexa.
English: For more information about treatment with Kivexa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Kivexa pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: Two studies used the active substances taken as separate medicines, while the third used a combination tablet for the once-daily dose.
Croatian: U dva su ispitivanja upotrijebljene djelatne tvari koje su se uzimale kao zasebni lijekovi, dok se u trećem upotrijebila kombinirana tableta u jednoj dnevnoj dozi.
English: Symptoms almost always include fever or rash, but also very commonly include nausea, vomiting, diarrhoea, abdominal pain, dyspnoea (difficulty breathing), cough, lethargy, malaise, headache, signs of liver damage in the blood and myalgia (muscle pain).
Croatian: Simptomi gotovo uvijek uključuju vrućicu ili osip, no također vrlo često uključuju i mučninu, povraćanje, proljev, abdominalnu bol, dispneju (otežano disanje), kašalj, letargiju, malaksalost, glavobolju, znakove oštećenja jetre u krvi i mijalgiju (mišićnu bol).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Kivexa.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist davanja odobrenja za stavljanje lijeka Kivexa u promet i svoje preporuke o uvjetima za primjenu tog lijeka.
English: The most common side effects with Kivexa (seen in between 1 and 10 patients in 100) are hypersensitivity (allergic reactions), rash, nausea (feeling sick), vomiting, diarrhoea, abdominal pain (stomach ache), headache, arthralgia (joint pain), muscle disorders, cough, nasal symptoms (nose problems, such as irritation and runny nose), fever, lethargy (lack of energy), tiredness, insomnia (difficulty sleeping), malaise (feeling unwell), loss of appetite and alopecia (hair loss).
Croatian: Najčešće nuspojave lijeka Kivexa (mogu se javiti u između 1 i 10 bolesnika na 100) su preosjetljivost (alergijske reakcije), osip, mučnina (osjećaj slabosti), povraćanje, proljev, abdominalna bol (bol u trbuhu), glavobolja, artralgija (bol u zglobovima), mišićni poremećaji, kašalj, nosni simptomi (problemi nosa, poput nadraženosti ili iscjetka iz nosa), vrućica, letargija (nedostatak energije), umor, nesanica (poteškoće sa spavanjem), malaksalost (osjećaj slabosti), gubitak apetita i alopecija (gubitak kose).
English: At the time of Kivexa's authorisation, abacavir was authorised at a dose of 300 mg twice a day.
Croatian: U trenutku izdavanja odobrenja za stavljanje u promet lijeka Kivexa, abakavir je bio odobren u dozi od 300 mg dvaput na dan.
English: A risk management plan has been developed to ensure that Kivexa is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Kivexa.